Summary
Interferon beta lb (Betaseron®) was licensed by the U.S. Federal Food and Drug Administration in July 1993 as the first treatment to alter the natural history of multiple sclerosis (MS). The drug, injected subcutaneously every other day, reduced the frequency of relapses and the expansion of central white matter pathology as measured by MRI. Twelve previous interferon trials in MS, employing a variety of interferon preparations, doses and routes of administration, preceded this trial and provided the scientific foundation for its success. Beta interferon therapy probably inhibits gamma interferon to achieve its therapeutic effect. Future MS therapy may require combination treatment with multiple agents with complimentary immunologic effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Basham TY, Merigan TC (1983) Recombinant interferon gamma increases HLA-DR synthesis and expression. J Immunol 130: 1492–1494
Bornstein MB, Johnson KP (1992) Treatment of multiple sclerosis with copolymer I. In: Rudick RA, Goodkin DE (eds) Treatment of multiple sclerosis. Trial design, results and future perspectives. Springer, Berlin Heidelberg New York Tokyo
Dhib-Jalbut SS, McFarlin DE (1990) Immunology of multiple sclerosis. Ann Allerg 64: 433–444
IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661
Jacobs L, Salazar AM, et al (1987) Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter, double-blinded study. Arch Neurol 44: 589–595
Johnson KP, Knobler RL, et al (1990) Recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis: pilot study results. Neurology 40 [Suppl 1]: 261
Knobler RL, Panitch HS, Braheny SL, et al (1984) Systemic alpha-interferon therapy of multiple sclerosis. Neurology 34: 1273–1279
Noronha A, Toscas A, Jensen MA (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27: 207–210
Panitch HS (1992) Interferons in multiple sclerosis. A review of the evidence. Drugs 44 (6): 946–962
Panitch HS, Bever CT jr (1993) Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimm 46: 155–164
Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097–1120
Paty DW, Li DKB, et al (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667
Sharief MK, Hentges R (1991) Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 325: 467–472
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag/Wien
About this paper
Cite this paper
Johnson, K.P. (1997). Role of interferons in demyelinating disease. In: Mizuno, Y., Youdim, M.B.H., Calne, D.B., Horowski, R., Poewe, W., Riederer, P. (eds) Advances in Research on Neurodegeneration. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6844-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6844-8_12
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82934-9
Online ISBN: 978-3-7091-6844-8
eBook Packages: Springer Book Archive